BIO-Partnering

Akaal Pharma has internally discovered novel small molecules as potent and selective modulators of Sphingosine 1-Phosphate receptors-1 (S1P1) with demonstrated superior safety profile in preclinical and clinical Phase-1 study. The candidate drug will be developed as First-in-Class for the treatment of neuropathy/pain and Best-in-Class for autoimmune/inflammatory diseases. The major advantages of our oral drug candidate are selectivity, receptor safety, reversible lymphopenia, cardio safety, broad therapeutic window and pharmacokinetics profile as multiple differentiation points.

The topical drug development with various products is a Phase-1 & 2 clinical developmental stage as First-in-class treatment of pruritus and skin diseases. These products have demonstrated safety and efficacy with no side effects of skin thinning and discoloration as is common in other class products. These proprietary products have displayed multimodal action against pruritus and inflammation, have fast onset of action, durable effect, safe and well tolerated.